Pierre Fabre Laboratories Receives the Galien International Prize for EBVALLO, the First Allogeneic Immunotherapy for Patients With a Rare Cancer
Pierre Fabre Laboratories Receives the Galien International Prize for EBVALLO, the First Allogeneic Immunotherapy for Patients With a Rare Cancer
CASTRES, France, June 21, 2024 /PRNewswire/ -- Pierre Fabre Laboratories has been awarded the "Prix Galien International" Prize in the "Best Product for a Rare/Orphan Disease" category for EBVALLO (tabelecleucel), indicated as monotherapy for the treatment of patients with post-transplant lymphoproliferative disorder positive for Epstein-Barr virus (EBV+ PTLD) who have received at least one prior treatment.
Pierre Fabre實驗室以EBVALLO (tabelecleucel)在單劑量療法下用於治療表達爲Epstein-Barr病毒(EBV+ PTLD)陽性的移植後淋巴增生性疾病患者(PTLD)至少已接受一種前期治療的藥品，獲得了“Prix Galien International”最佳罕見/孤兒疾病類別產品獎。
During the same ceremony, EBVALLO received the "Prix Galien" Italy Award in the Advanced Therapy Medicinal Product category. These two exceptional recognitions follow the awarding of EBVALLO for the "Prix Galien France" on December 2023
在同一頒獎典禮上，EBVALLO榮獲“Prix Galien”意大利先進療法藥品類別獎項。這兩個卓越獎項的頒發緊隨EBVALLO於2023年12月獲得“Prix Galien France”獎項。
As a symbol of scientific rigor, excellence, and innovation, the "Prix Galien International" awards remarkable recent health innovations available to the public, following an evaluation done by an independent committee of experts. Today this prize exists in fifteen countries, its reputation and influence have made it the most prestigious distinction in the medical field. Through this prize, the jury honors EBVALLO, thanks to its innovative manufacturing process and mechanism of action. It offers rapid and lasting clinical results in over 50% of cases, in a rare disease with a particularly unfavorable prognosis, leading to significant morbidity and mortality.
作爲科學嚴謹、卓越和創新的象徵，“Prix Galien International”向公衆提供了傑出的新近健康創新，經過獨立專家委員會的評估後獲得了這個獎項。如今，這個獎項在十五個國家都有，它的聲譽和影響使其成爲醫學領域最負盛名的榮譽。通過這個獎項，評審委員會讚賞EBVALLO的創新制造工藝和作用機制。它在一種預後極劣的罕見病中，在超過50%的病例中提供了快速和持久的臨床結果，導致重大的發病率和死亡率。
This award highlights the innovation capacity of Pierre Fabre Laboratories in oncology, one of its priority areas of development, and its ability to establish successful collaborations, such as the one with Atara Biotherapeutics (ATARA), an American biotech company. A global agreement was signed in December 2023, providing Pierre Fabre Laboratories with the EBVALLO development, manufacturing, and commercialization rights all over the world. EBVALLO was approved by the European Medicines Agency (EMA) in December 2022, and to date, this promising new treatment is marketed in Germany and Austria. In Europe, EBVALLO is available to patients as part of an Early Access Program since July 2023.
此次獎項突出了Pierre Fabre實驗室在腫瘤學領域的創新能力，也是其發展優先領域之一，而且它具備建立成功合作關係的能力，例如與美國生物技術公司Atara Biotherapeutics (ATARA)的合作。於2023年12月簽署了一項全球協議，爲Pierre Fabre實驗室提供了EBVALLO在全球範圍內的開發、製造和商業化權利。EBVALLO於2022年12月獲得歐洲藥品管理局(EMA)批准，在德國和奧地利上市銷售。在歐洲，自2023年7月以來，EBVALLO作爲早期接觸計劃的一部分，已經對患者開放。
"We are very proud to receive this award, which we dedicate to the patients. It is a recognition of the major therapeutic advancement that EBVALLO represents for patients with a rare cancer and a very unfavorable prognosis, who until now had significant unmet needs. This cancer, which affects a few hundred people worldwide each year, resonates perfectly with our purpose: every time we take care for a single person, we make the whole world better." said Éric Ducournau, CEO of the Pierre Fabre Laboratories.
“我們非常自豪地獲得了這個獎項，我們把它獻給患者。這是對EBVALLO在少數癌症患者中所代表的重大治療進展的認可，這些患者預後極差，直到現在仍需求助於之前無法滿足的需求。這種癌症每年在全球隻影響到少數幾百人，它與我們的宗旨完美契合：每當我們爲一個人提供護理時，我們都讓整個世界變得更好。”Pierre Fabre實驗室CEO Éric Ducournau 表示:“我們非常自豪地獲得了這個獎項，我們把它獻給患者。”
CONTACT: Laurence MARCHAL, [email protected]
聯繫人：Laurence MARCHAL，[email protected]
PDF-
Photo -
Logo -
PDF-
照片-
標誌 -
SOURCE Pierre Fabre
來源Pierre Fabre
譯文內容由第三人軟體翻譯。